Long‐term outcomes after prophylactic ICD and CRT‐D implantation in nonischemic patients: Analysis from a nationwide database of daily remote‐monitoring transmissions
- 4 June 2019
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (9) , 1626-1635
Abstract
Introduction: Clinical trials did not provide conclusive evidence concerning the benefit of prophylactic implantable cardioverter‐defibrillators (ICDs) in patients with severe nonischemic cardiomyopathy (NICM). We aimed to compare incidence of appropriate sustained ventricular arrhythmia (SVA) and device therapy in ischemic cardiomyopathy (ICM) vs NICM ICD and/or cardiac resynchronization therapy (CRT‐D) patients.Methods and Results: We analyzed remote‐monitoring data from devices of the Home Monitoring Expert Alliance network. SVA recordings were adjudicated by three independent electrophysiologists. Our cohort included 1,946 patients who received either an ICD (55%) or a CRT‐D (45%) for primary prevention of sudden cardiac death. Median (interquartile range) age was 70 (62‐77) years, 81% were male, and 52% were in the ICM group. Patients were remotely monitored for a maximum follow‐up of 5 years. The 5‐year product‐limit estimate of SVA incidence in patients with an ICD was 47.3% (95% confidence interval [CI], 41.0%‐53.9%) in the ICM group and 44.7% (36.9%‐53.3%) in the NICM group. In patients with a CRT‐D, SVA incidence was 45.7% (37.3%‐55.0%) in ICM patients and 49.2% (40.4%‐58.7%) in NICM patients. The adjusted hazard ratio for SVA in the ICM vs NICM group was 0.96 (95% CI: 0.70‐1.30, P = .77) in ICD patients and 0.85 (95% CI: 0.61‐1.18, P = .34) in CRT‐D patients. SVAs triggered appropriate device therapies with similar incidence in all groups.Conclusion: In a large cohort of remotely monitored ICD and CRT‐D recipients, SVA incidence did not significantly differ in ICM and NICM patients.Keywords
This publication has 18 references indexed in Scilit:
- Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trialsEuropean Heart Journal, 2017
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart FailureNew England Journal of Medicine, 2016
- Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device TherapyCirculation: Heart Failure, 2010
- Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy?Circulation, 2006
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic CardiomyopathyJAMA, 2004
- Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated CardiomyopathyNew England Journal of Medicine, 2004
- Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart FailureNew England Journal of Medicine, 2004
- Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated CardiomyopathyCirculation, 2002
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002